VA-DISYS
7.4.2021 15:02:11 CEST | Business Wire | Press release
Digital Intelligence Systems, LLC (DISYS) and Signature Consultants, LLC announce today that an agreement was signed for DISYS to acquire the legal entities of Signature, combine operations, and create one of the largest providers of information technology (IT) staffing services in the U.S. With combined annual revenues of $860M, the organization will also be the second largest minority-owned staffing firm in the nation. Both businesses will maintain their respective brands in the marketplace for the foreseeable future.
The combined operations will draw on the resources of more than 7,500 employees and consultants, serving clients from more than 40 offices, eight countries, and four delivery centers worldwide. Together, the IT firm will offer capabilities in staffing and recruiting, managed services programs (MSPs), consulting and project management, and automation support.
The current DISYS CEO, Mahfuz Ahmed, will serve as the CEO of the combined organization. Dr. Jay Cohen, founder and former CEO of Signature, will remain with the new entity to continue his oversight of day-to-day functioning of Signature operations and to focus on the cultural integration of the newly- combined organization. The senior leadership teams of both organizations will also remain intact.
“For DISYS, combining forces with Signature is a great strategic fit for both of our organizations, this brings expanded opportunities as we continue to diversify our account portfolio and puts us within striking distance of becoming a $1B firm,” said Mahfuz Ahmed, DISYS’ CEO. “DISYS and Signature share attributes that create a synergistic whole and we believe our complementary service offering will enable us to reach new levels of growth. We are stronger together and look ahead to a bright future as we continue to set the standard for the staffing and solutions industry.”
Both companies take great pride in sharing similar values, including collaboration, respect, accountability, fairness, and ingenuity, as well as bringing deep expertise to engagements. The combined company will continue to deepen its technical leadership to deliver high quality service and client-driven results.
“DISYS’ strong operations, successful brand, core values, and exceptional industry practices make them an excellent strategic partner for us,” says Dr. Jay Cohen, founder of Signature. “The combination of our two organizations creates a powerful force in the industry, expanding our clients’ access to an even greater array of IT and professional talent and specialized services and providing enhanced opportunities for our consultants and employees to further their skill development and careers.”
The transaction will be funded through debt financing provided by Wells Fargo Bank and The Carlyle Group. Carlyle’s $56 billion Global Credit platform made the investment with capital primarily from its Credit Opportunities franchise. The Credit Opportunities franchise invests in privately negotiated capital solutions primarily for upper middle market borrowers, including both private equity sponsored and family or entrepreneur-owned companies.
Alex Popov, Carlyle’s Head of Illiquid Credit Strategies, said, “We are excited to partner with industry-leading founders at DISYS and Signature, who have built strong, complementary businesses meeting a growing need for IT staffing, and to provide capital to help them better serve clients and support strategic growth objectives.”
“Wells Fargo is proud to continue our longstanding relationship with DISYS and provide a flexible, asset-based lending solution to support this exciting growth,” said Raphael Torres, Managing Director, Wells Fargo Commercial Capital, Staffing Services Group. “We are honored to be part of this next chapter alongside DISYS’s innovative management team and to continue supporting this strong, minority-owned business with their working capital needs.”
Wells Fargo Commercial Capital continues as the asset-based lender for DISYS. Wells Fargo Securities, LLC served as the exclusive financial advisor to Signature Consultants while Deloitte Consulting provided advisory services on behalf of DISYS.
About Digital Intelligence Systems, LLC (DISYS)
DISYS, founded in 1994 and headquartered in McLean, Virginia, is a global managed services and staffing firm with 33 offices and 4 delivery centers worldwide. As a leading global enterprise, DISYS’ experts are thought leaders in the industry, who bring best-in-class expertise to more than 250 Fortune 500 companies. Recognized as a Top 20 Staffing Provider and one of the Largest Staffing Firms in the U.S., as well as a leading Diversity Staffing Firm by Staffing Industry Analysts (SIA), DISYS is also a certified Minority Business Enterprise (MBE) and Top Supplier to 7 of 10 leading global MSPs. With the support of almost 5,000 internal and external (consultant) employees, DISYS specializes in Global Staffing, Application Development Services, Business Intelligence Services, Cloud Enablement Services, Infrastructure Support Services, Enterprise Apps as-a-Service, Automated Testing, and Process Automation. For more information on the company, please visit www.disys.com .
About Signature Consultants, LLC
Headquartered in Fort Lauderdale, Florida, Signature Consultants was established in 1997 with a singular focus: to provide clients and consultants with superior staffing solutions. With 29 locations throughout North America, Signature annually deploys thousands of consultants to support, run and manage their clients’ technology needs. Signature offers IT staffing, consulting, managed solutions, and direct placement services. For more information on the company, please visit https://www.sigconsult.com . Signature Consultants is the parent company to Hunter Hollis and Madison Gunn .
About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Investment Solutions. With $246 billion of assets under management as of December 31, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs 1,825 people in 29 offices across five continents. Further information is available at www.carlyle.com . Follow The Carlyle Group on Twitter @OneCarlyle
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005257/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom